Should I buy or sell Milestone Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MIST shares. View MIST analyst ratings or view top-rated stocks .

What is Milestone Pharmaceuticals' stock price target for 2024?

4 Wall Street analysts have issued 12 month price targets for Milestone Pharmaceuticals' stock. Their MIST share price targets range from $4.00 to $25.00. On average, they anticipate the company's share price to reach $10.75 in the next twelve months. This suggests a possible upside of 514.3% from the stock's current price. View analysts price targets for MIST or view top-rated stocks among Wall Street analysts .

How have MIST shares performed in 2024?

Milestone Pharmaceuticals' stock was trading at $1.67 at the beginning of 2024. Since then, MIST shares have increased by 4.8% and is now trading at $1.75. View the best growth stocks for 2024 here .

When is Milestone Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MIST earnings forecast .

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02.

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , CymaBay Therapeutics (CBAY) , iBio (IBIO) , Allena Pharmaceuticals (ALNA) , Fulcrum Therapeutics (FULC) , OPKO Health (OPK) , VYNE Therapeutics (VYNE) , Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX) .

When did Milestone Pharmaceuticals IPO?

Milestone Pharmaceuticals (MIST) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MIST

Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free MIST Stock Alerts

$1.75

-0.01 (-0.57%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.70
▼
$1.82
50-Day Range: $1.42
▼
$2.20
52-Week Range: $1.33
▼
$4.49

Volume: 112,672 shs
Average Volume: 323,887 shs
Market Capitalization: $93.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.75

Get Milestone Pharmaceuticals alerts:

Milestone Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 514.3% Upside
$10.75 Price Target
Short Interest: Healthy
1.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.15) to ($1.54) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.30 out of 5 stars

Medical Sector

737th out of 913 stocks

Pharmaceutical Preparations Industry

322nd out of 402 stocks

3.4

Analyst's Opinion

Consensus Rating
Milestone Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Milestone Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.05% of the outstanding shares of Milestone Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Milestone Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Milestone Pharmaceuticals has recently increased by 16.54%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Milestone Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Milestone Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MIST.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 3 news articles for Milestone Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for MIST on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
4 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.40% of the stock of Milestone Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Milestone Pharmaceuticals are expected to decrease in the coming year, from ($1.15) to ($1.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Milestone Pharmaceuticals is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Milestone Pharmaceuticals is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Milestone Pharmaceuticals has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Milestone Pharmaceuticals Stock (NASDAQ:MIST)

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

MIST Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MIST Stock News Headlines

April 17, 2024 | finance.yahoo.com

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

April 17, 2024 | globenewswire.com

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

April 17, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 8, 2024 | finance.yahoo.com

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

April 8, 2024 | globenewswire.com

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

April 3, 2024 | finance.yahoo.com

Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

April 1, 2024 | globenewswire.com

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

March 28, 2024 | finance.yahoo.com

Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

April 17, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

March 22, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Milestone Pharmaceuticals (MIST)

March 21, 2024 | markets.businessinsider.com

Milestone Pharmaceuticals’ Etripamil Nears Approval: A Strong Buy Recommendation

March 21, 2024 | investorplace.com

MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023

March 21, 2024 | globenewswire.com

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

February 29, 2024 | globenewswire.com

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

February 29, 2024 | globenewswire.com

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

February 28, 2024 | marketwatch.com

Milestone Pharma Shares Drop After Public Offering News

February 28, 2024 | msn.com

Milestone Pharmaceuticals launches stock and warrants offering

February 28, 2024 | globenewswire.com

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

February 26, 2024 | markets.businessinsider.com

Milestone Pharmaceuticals Earns Buy Rating on Strong Regulatory and Financial Outlook

February 26, 2024 | msn.com

Why Milestone Pharmaceuticals (MIST) Stock Is Rising

February 26, 2024 | finance.yahoo.com

Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT

February 21, 2024 | benzinga.com

Milestone Pharmaceuticals Stock (NASDAQ:MIST) Insider Trades

February 13, 2024 | marketwatch.com

Merrimack Pharmaceuticals to Get $225M Milestone Payment After FDA's Supplemental NDA Approval

February 11, 2024 | finance.yahoo.com

Milestone Pharmaceuticals Inc. (MIST)

January 31, 2024 | reuters.com

Novartis eyes 5% annual sales growth through 2028

January 25, 2024 | businesswire.com

Dr. Ferrer BioPharma Awarded Winner at CPHI Pharmapack 2024 for Groundbreaking GentleMist Technology

January 20, 2024 | stockhouse.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST

See More Headlines

Receive MIST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MIST
CUSIP: N/A
CIK: 1408443
Web: www.milestonepharma.com
Phone: (514) 336-0444
Fax: N/A
Employees: 47
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.75
High Stock Price Target: $25.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +514.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-59,690,000.00
Net Margins: N/A
Pretax Margin: -5,968.50%
Return on Equity: -170.99%
Return on Assets: -64.45%

Debt

Debt-to-Equity Ratio: 2.97
Current Ratio: 10.11
Quick Ratio: 10.11

Sales & Book Value

Annual Sales: $1 million
Price / Sales: 93.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.50 per share
Price / Book: 3.50

Miscellaneous

Outstanding Shares: 53,150,000
Free Float: 47,622,000
Market Cap: $93.01 million
Optionable: Optionable
Beta: 1.77

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Joseph G. Oliveto M.B.A. (Age 56)
CEO, President & Director
Comp: $905.71k
Mr. Amit Hasija (Age 51)
CFO & Executive VP of Corporate Development
Comp: $603.18k
Dr. David B. Bharucha FACC (Age 62)
M.D., Ph.D., Chief Medical Officer
Comp: $440.67k
Dr. Philippe Douville M.B.A. (Age 62)
Ph.D., Founder, Strategic Advisor & Member of Scientific Advisory Board
Mr. Jeff Nelson (Age 43)
Chief Operating Officer
Ms. Kim Fox
Vice President of Communications
Dr. Philip T. Sager FACC (Age 68)
FAHA, FHRS, M.D., Chief Medical Advisor & Member of the Scientific Advisory Board
Dr. Guy Rousseau
SVP of Regulatory Affairs and Quality Management
Ms. Anita Holz
VP & Head of Medical Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MIST Stock Analysis - Frequently Asked Questions

Should I buy or sell Milestone Pharmaceuticals stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MIST shares.
View MIST analyst ratings or view top-rated stocks.
What is Milestone Pharmaceuticals' stock price target for 2024?: 4 Wall Street analysts have issued 12 month price targets for Milestone Pharmaceuticals' stock. Their MIST share price targets range from $4.00 to $25.00. On average, they anticipate the company's share price to reach $10.75 in the next twelve months. This suggests a possible upside of 514.3% from the stock's current price.
View analysts price targets for MIST or view top-rated stocks among Wall Street analysts.
How have MIST shares performed in 2024?: Milestone Pharmaceuticals' stock was trading at $1.67 at the beginning of 2024. Since then, MIST shares have increased by 4.8% and is now trading at $1.75.
View the best growth stocks for 2024 here.
When is Milestone Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MIST earnings forecast.

How were Milestone Pharmaceuticals' earnings last quarter?: Milestone Pharmaceuticals Inc. (NASDAQ:MIST) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.02.
What other stocks do shareholders of Milestone Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CymaBay Therapeutics (CBAY), iBio (IBIO), Allena Pharmaceuticals (ALNA), Fulcrum Therapeutics (FULC), OPKO Health (OPK), VYNE Therapeutics (VYNE), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX).
When did Milestone Pharmaceuticals IPO?: Milestone Pharmaceuticals (MIST) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
How do I buy shares of Milestone Pharmaceuticals?: Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MIST) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial